Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + iCo-007
- Development stage
- Unknown
- Lead developer
- iCo Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Ranibizumab + iCo-007 is a combination of two investigational and approved agents for the treatment of diabetic macular edema (DME). Ranibizumab is a recombinant, humanized monoclonal antibody fragment that binds to and inhibits all isoforms of vascular endothelial growth factor A (VEGF-A), thereby preventing abnormal blood vessel growth and leakage in the eye. It is approved for several retinal diseases, including DME. iCo-007 is a second-generation antisense oligonucleotide that targets C-Raf kinase mRNA, downregulating its expression and thereby inhibiting multiple growth factors involved in angiogenesis and vascular permeability, such as VEGF, IGF-1, and HGF. The combination has been studied in clinical trials to assess safety and efficacy in DME patients[3][5][4].
- Brand names
- Lucentis
- Other names
- ranibizumabiCo 007iCo007iCo-007
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ranibizumab + iCo-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + iCo-007.